Bayer Aktiengesellschaft (BAYNN.MX)
| Previous close | 541.80 |
| Open | 0.00 |
| Bid | 517.50 x 200 |
| Ask | 550.00 x 52000 |
| Day's range | 541.80 - 541.80 |
| 52-week range | 541.80 - 1,189.81 |
| Volume | |
| Avg. volume | 912 |
| Market cap | 529.045B |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | 11.31 |
| EPS (TTM) | 47.91 |
| Earnings date | 06 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Further weakness as Bayer (ETR:BAYN) drops 3.3% this week, taking one-year losses to 49%
It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...
Yahoo Finance UKStocks to watch this week: Burberry, Vodafone, BT and Walmart
Earnings preview of key companies reporting this week and what to look out for.
- Yahoo Finance Video
Bayer CEO: Now is not the time to break the company up
Life sciences company Bayer (BAYRY, BAYN.DE) isn't breaking itself up right now. Bayer CEO Bill Anderson says, "This is not a good time to be... breaking up the firm," given the company's need to rebuild its pharmaceutical pipeline and battle the ongoing litigation stemming from the weedkiller Roundup. When it comes to the Roundup lawsuits, Bayer has "adequately provisioned" for the costs of those suits, Anderson says. Overall, "the fundamental fact is, that glyphosate, Roundup, is safe," Anderson states, adding that Bayer is "a scientifically-driven company and we have this litigation thing that's not scientific." On the pharmaceutical business, Anderson says the group is "in a bit of a transition phase." "We got a couple of major medicines that are losing patent protection over the next few years. So we are busy rebuilding the pipeline right now," he tells Yahoo Finance. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.
